Ganz, Joranson receive ACS Distinguished Service Award

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 11
Volume 16
Issue 11

The American Cancer Society has given its Distinguished Service Award to Patricia Ganz, MD, director of cancer prevention and control research at UCLA's Jonsson Cancer Center, and to David E. Joranson, MSSW, Distinguished Scientist and recently retired director of the Pain and Policy Studies Group at the University of Wisconsin Carbone Comprehensive Cancer Center.

ATLANTA—The American Cancer Society has given its Distinguished Service Award to Patricia Ganz, MD, director of cancer prevention and control research at UCLA's Jonsson Cancer Center, and to David E. Joranson, MSSW, Distinguished Scientist and recently retired director of the Pain and Policy Studies Group at the University of Wisconsin Carbone Comprehensive Cancer Center.

Dr. Ganz, a professor in the UCLA Schools of Medicine and Public Health and a founding member of the National Coalition for Cancer Survivorship, was recognized for her major contributions and commitment in the field of cancer research. For 2 decades, Dr. Ganz has conducted ground-breaking research that has changed the face of cancer survivorship. Last year, she was selected to head up the UCLA-Livestrong Survivorship Center of Excellence, which addresses the needs of the ever-increasing number of cancer survivors in the United States.

Mr. Joranson was honored for his contributions to the study and modernization of narcotics control policies to remove barriers to pain patients' access to opioid analgesics, ACS said. As director of the World Health Organization Collaborating Center for Policy and Communications in Cancer Care, he has led efforts to achieve more balanced national drug control policies and improve patient access to pain drugs in developing countries.

Recent Videos
9 Experts are featured in this series.
Vinay K. Puduvalli, MD, is featured in this series.
Genetic consultation and next-generation sequencing can also complement treatment strategies for patients with pancreatic cancer.
An advanced computation linguistics model that can detect pancreatic cysts can help patients prevent pancreatic tumors from forming.
Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors.
Immunotherapy options like CAR T-cell therapy and antigen-presenting cell-directed agents are currently being evaluated in the pancreatic cancer field.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
Related Content